We provide more colour in this note on our change in TP and recommendation following ASMi FY25 results, which were good given the improved outlook. We see upside on the FY26 estimates, yet expectations for FY27 are already high and leave little room for upside, while the valuation is also above the historical average. We derive a fair value of €658 p.s. based on our FY27 diluted EPS of € 22.1 and a PE multiple of 30x. Given the downside we reduced our recommendation this morning from Accumulate ...
According to Bloomberg, D'Ieteren Group has appointed Rotschild to explore strategic options for its controlling stake in Belron, people familiar with the matter said. Options considered include an IPO in the US or in the EU, with a valuation of upwards of $30bn and close to $40bn. Deliberations are preliminary and D'Ieteren could decide to keep its stake in Belron, people said. Any IPO plan would need to be agreed by the entire ownership of Belron, including CD&R, H&F, GIC and Blackrock. In thi...
Aedifica and Cofinimmo: Aedifica acquires c.80% of the shares in Cofinimmo. ASM International: 4Q25 results; strong FY26 guidance. D'Ieteren: Bloomberg reports on Belron IPO, valuation above $30bn, close to $40bn. dsm-firmenich: Symrise 2025 results and guidance. Kinepolis: Feb reassures - US box office revenue up +1% YoY, France visitors up +25% YoY. KPN: Odido data breach
UCB and Antengene entered into an exclusive worldwide license agreement to further develop, manufacture and commercialize ATG-201, a preclinical CD19/CD3 bispecific T-cell engager. UCB will pay $ 80m in upfront and near-term milestone payments, development and commercial milestones of up to approx. $ 1.1bn, and royalties on future sales. ATG-201, being a bispecific T-cell engager, builds on UCB's autoimmune expertise, and given its potential to address a broad set of B-cell driven autoimmune dis...
ASM reports Q4 and full-year 2025 results Almere, The NetherlandsMarch 3, 2026, 6 p.m. CETDouble‑digit growth in 2025, strong 2026 ahead ASM International N.V. (Euronext Amsterdam: ASM) today reports its Q4 and full year 2025 results (unaudited). Orders of €803 million in Q4 2025 showed a solid rebound, driven by strong demand in the advanced logic/foundry market and a quarter-end recovery in demand from Chinese customers. Revenue of €698 million in Q4 2025 exceeded previous guidance of €630–660 million. Full year 2025 revenue was up 12% at constant currency, driven by advanced logic/fo...
Aedifica NV/SA – Results for the Initial Acceptance Period of Aedifica’s Exchange Offer for all Cofinimmo shares More information is available on Aedifica’s website via the link below and can be accessed subject to the usual restrictions.
Allfunds Group plc: Business as usual. Basic-Fit: Good news - senior unsecured convertible bonds due 2028 put option waiver. D'Ieteren: Belgian February new car registrations down 7.7%, VW down 13.1% EVS: Analyst meeting feedback. Sif Group: Preview - order intake window rapidly closing. Wereldhave: €250m refinanced
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.